According to latest Wolters Kluwer data released today, Zubsolv tablets market share were down 0.13 percentage points from last week to 5.94%,. The four week rolling average were also slightly lower, reaching a market share of 6.03%. Zubsolv TRx market share were 5.39% for the week. The four week rolling average were also lower reaching a market share of 5.49%. Monthly buprenorphine/naloxone unit sales showed a y/y growth rate of 8.6%, unchanged from last week. TRx showed a y/y growth rate of 4.8% and this were also unchanged.